HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
October 20 2022 - 9:00AM
Heart Test Laboratories, Inc. d/b/a
HeartSciences
(NASDAQ: HSCS; HSCSW) (“HeartSciences” or the
“Company”), a medical technology company focused on saving
lives by making an ECG (also known as an EKG) a far more
valuable screening tool through the use of AI, today announced it
was recognized by MedTech Outlook Magazine as a 2022 Top 10 MedTech
startup highlighting the Company’s MyoVista device.
MedTech Outlook aims to bridge the gap between
MedTech Technology providers and Healthcare facilities / Medical
institutes. MedTech Outlook monitors and informs about
the MedTech trends, challenges, and solutions. In announcing
the MedTech Top 10 startups, MedTech Outlook stated, “Medtech
startups are, in many ways, reshaping the modern healthcare
industry and presenting some promising solutions to change how
physicians and researchers approach the mitigation of patient
needs. Looking ahead, a wide selection of medtech startups are
poised to bring the latest technological trends to the fore and
develop solutions best suited to satisfy the demands of future
medical needs.”
To read HeartSciences’ full feature please
visit: https://www.medicaltechoutlook.com/heartsciences.
“Heart disease is the leading cause of death
around the world. We believe our device, the MyoVista, has the
potential to help save lives,” states Andrew Simpson, CEO of
HeartSciences. “The problem we’re seeking to solve is well known.
Millions of people with heart disease remain undiagnosed until some
sort of event that could have been preventable through early
detection. That’s why our MyoVista device is designed to
significantly increase the clinical value of the ECG by detecting
cardiac dysfunction at an early stage. Our objective is to become a
fixture in front-line healthcare settings to help physicians make
better and earlier referral decisions for at risk patients.”
About HeartSciencesHeart Test
Laboratories, Inc. d/b/a HeartSciences is medical technology
company focused on applying innovative AI-based technology to an
ECG (also known as an EKG) to expand and improve an ECG’s clinical
usefulness. Millions of ECGs are performed every week and the
Company’s objective is to improve healthcare by making an ECG a far
more valuable cardiac screening tool, particularly in frontline or
point-of-care clinical settings. HeartSciences’ first product
candidate for FDA clearance, the MyoVista wavECG, or the MyoVista,
is a resting 12-lead ECG that is also designed to provide
diagnostic information related to cardiac dysfunction which has
traditionally only been available through the use of cardiac
imaging. The MyoVista also provides conventional ECG information in
the same test. The business model, which involves the use of the
MyoVista device and consumables for each test, is expected to be
“razor-razorblade” as the electrodes used with the MyoVista are
proprietary to HeartSciences, and new electrodes are required for
every test performed.
For more information, please visit:
https://www. heartsciences.com.
Twitter: @HeartSciences
About MedTech Outlook
The medical technology is always evolving and is
a major cogwheel of healthcare system. The MedTech evolution and
its manifestation have been effective in prevention, diagnosis,
treatment and management of ailments and rehabilitation from
illnesses. MedTech has pervaded not only every anatomical
categorization but also the healthcare facility ecosystem. The
rapid innovation has along with the numerous benefits thrown a
different set of challenges across design, validation and
regulation.MedTech Outlook will serve to be a platform that bridges
the spectrum between MedTech Technology providers and the
Healthcare facilities/ Medical institutes. We strive to monitor and
inform about the MedTech trends, challenges and solutions. MedTech
Outlook wants to assist purchasers/procurers, decision makers and
heads of operations/healthcare managers from peer vetted
authoritative contributions.The magazine will be following a unique
learn-from-peer approach where the decision makers and experts will
be sharing their invaluable views about medical technologies which
have had an impact in providing the healthcare.Safe Harbor
StatementThis announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company's future financial and operating
performance. All statements, other than statements of historical
facts, included herein are "forward-looking statements" including,
among other things, statements about HeartSciences’ beliefs and
expectations. These statements are based on current expectations,
assumptions and uncertainties involving judgments about, among
other things, future economic, competitive and market conditions
and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond the
Company's control. The expectations reflected in these
forward-looking statements involve significant assumptions, risks
and uncertainties, and these expectations may prove to be
incorrect. Investors should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Potential risks and uncertainties include, but are
not limited to, risks discussed in HeartSciences’ filings with the
U.S. Securities and Exchange Commission at www.sec.gov. Other than
as required under the securities laws, the Company does not assume
a duty to update these forward-looking statements.
For investor and media inquiries, please
contact:Investor Relations:Crescendo
Communications, LLCPhone: (212)
671-1021Email: HSCS@crescendo-ir.com
Company:Gene GephartPhone:
+1-737-414-9213
(US)Email: investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Apr 2023 to Apr 2024